Ryan Locke: New ARPA-H funding opportunity in cancer screening
Ryan Locke, Associate at Booz Allen Hamilton, posted on LinkedIn:
“New ARPA-H funding opportunity in cancer screening
Cancer is all over the news (see NY Times article below!) and cancer screening is a critical step to a cancer future. FDA’s approval of Shield blood test is an important step forward and development of many new innovative ways to detect cancer earlier will help patients. ARPA-H may help that happen via a new funding opportunity called ‘Platform Optimizing SynBio for Early Intervention and Detection in Oncology’ (POSEIDON). There are numerous details within the POSIEDON solicitation and special notice on sam.gov.
Read the details on POSEIDON in the press:
Register here to discuss the details of the solicitation in person with the program manager and team.
Apply here with your innovative solutions to the solicitation.
NYT recent news.”
Source: Ryan Locke/LinkedIn